Drugs / Fludeoxyglucose
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02886793 | Jun 2016 → Jul 2018 | pulmonary hypertension | Joan Albert Barbera Mir | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03262389 | Sep 2017 → Nov 2019 | plasma cell myeloma | Michael C Roarke, MD | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fludeoxyglucose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03262389 ↗ |
| Known as | F-18 FDG | “Fludeoxyglucose (F-18 FDG) PET/MRI” NCT03262389 ↗ |
| Modality | Diagnostic / imaging agent | “FDG-PET” NCT02886793 ↗ |
| Route | Intravenous | “Route of administration is intravenous.” NCT03262389 ↗ |